NEW YORK: The battle for several million dollars worth of PR work
is on. Two pharmaceutical giants have issued RFPs for potential
blockbuster drugs now being launched in the US.
Aventis, the French-German pharma company, has offered RFPs for its
popular insulin tablet Amaryl and newcomer Lantus. Schering-Plough,
which produces allergy medication Claritin, has an RFP in review for its
new allergy drug Clarinex.
Aventis grossed $20 billion during 2000, according to its
website. Amaryl was one of its fastest growing drugs, increasing 55.8%
between 1999 and 2000. It is not known how much the RFP for Amaryl is
Lantus, which was officially introduced to the US on May 10, is an
injection based insulin drug. Lantus currently accounts for 28% of
insulin drug profits in Germany. According to various sources, the
Lantus RFP is worth $2 million. Fleishman-Hillard used to
Schering-Plough hopes to switch users of Claritin, its $3 billion
dollar allergy empire, to Clarinex. Schering-Plough would neither
confirm nor deny that an RFP was issued.